{
    "2020-04-30": [
        [
            {
                "time": "2020-04-30",
                "original_text": "资金提前动手了 硬核科技股“王者归来” 节后行情值得期待(附一季报业绩大增优质个股名单)",
                "features": {
                    "keywords": [
                        "硬核科技股",
                        "王者归来",
                        "节后行情",
                        "一季报业绩大增"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "【招商策略】2020年4月陆股通持股分析——北上资金放量回流，加仓食品饮料、医药和电子",
                "features": {
                    "keywords": [
                        "北上资金",
                        "放量回流",
                        "食品饮料",
                        "医药",
                        "电子"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "食品饮料",
                        "医药",
                        "电子"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "研发日报丨基石Avapritinib临床失败 罗氏Risdiplam再达3期终点",
                "features": {
                    "keywords": [
                        "Avapritinib",
                        "临床失败",
                        "Risdiplam",
                        "3期终点"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "恒瑞医药员工卷入行贿案：年销售费用近百亿，受贿医生被判7年 其他违规处罚",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "行贿案",
                        "销售费用",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "13亿品种，投入研发2844万，恒瑞拿下非布司他片一致性评价",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "非布司他片",
                        "一致性评价",
                        "研发投入"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "成立以来累计亏损超5000万 南华基金何时脱困？",
                "features": {
                    "keywords": [
                        "南华基金",
                        "累计亏损",
                        "脱困"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "基金"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "未来十年是医药股黄金十年，创新药公司将呈现三大主线",
                "features": {
                    "keywords": [
                        "医药股",
                        "黄金十年",
                        "创新药公司",
                        "三大主线"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "A股一季报显韧性：7成公司盈利 机构扎推医药等龙头",
                "features": {
                    "keywords": [
                        "A股",
                        "一季报",
                        "盈利",
                        "医药龙头"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "QFII一季度青睐白马股，重仓银行医药电子",
                "features": {
                    "keywords": [
                        "QFII",
                        "白马股",
                        "银行",
                        "医药",
                        "电子"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "银行",
                        "医药",
                        "电子"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-04-30",
                "original_text": "郑眼看盘：假期风险有限 可以持股过节",
                "features": {
                    "keywords": [
                        "假期风险",
                        "持股过节"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "affected_by_time_series": "false"
                }
            }
        ]
    ]
}